Key result
Interleukin-18 is a proinflammatory cytokine implicated in acute myocardial infarction and heart failure, with IL-18 binding protein and neutralizing antibodies emerging as potential therapeutic targets.
This review highlights the pathophysiological role of the proinflammatory cytokine IL-18 in cardiovascular disease and discusses the potential of IL-18 binding proteins and neutralizing antibodies as novel therapeutic strategies for acute myocardial infarction and heart failure.
No takes yet. Share an insight, caveat, or question.
IL-18 inhibition merits trial evaluation in AMI and HF; leaves open clinical translation from preclinical and observational data.
O’Brien et al. (2014) conducted a review in Acute Myocardial Infarction and Heart Failure. IL-18 binding protein (IL-18BP) and neutralizing IL-18 antibody was evaluated. Interleukin-18 is a proinflammatory cytokine implicated in acute myocardial infarction and heart failure, with IL-18 binding protein and neutralizing antibodies emerging as potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: